Certara, a pharmaceutical company, completed the acquisition of Vyasa Analytics, a software developer. Financial terms were not disclosed. “We are pleased to announce the acquisition of Vyasa, a cutting-edge company that will enhance existing Certara software platforms and further expand our capabilities across our product portfolios. By incorporating AI into our suite of products, we are building capabilities that will continue to expand our leadership for biosimulation use cases in drug research and development," William F. Feehery, Certara CEO.